within Pharmacolibrary.Drugs.ATC.L;

model L04AX03_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.64,
    Cl             = 0.00012466666666666667,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0125,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00535,
    Tlag           = 11.4
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AX03_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Methotrexate is an antimetabolite and antifolate drug, widely used in the treatment of various cancers (e.g., leukemia, lymphoma, breast cancer) and autoimmune diseases such as rheumatoid arthritis and psoriasis. It inhibits dihydrofolate reductase, blocking DNA synthesis and cell replication. Methotrexate is approved and used in clinical practice today for both oncological and non-oncological indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters after oral administration in adult patients with rheumatoid arthritis. Oral bioavailability varies.</p><h4>References</h4><ol><li><p>Hebing, RC, et al., &amp; de Jonge, R (2023). Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial. <i>Annals of the rheumatic diseases</i> 82(4) 460–467. DOI:<a href=&quot;https://doi.org/10.1136/ard-2022-223398&quot;>10.1136/ard-2022-223398</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36543526/&quot;>https://pubmed.ncbi.nlm.nih.gov/36543526</a></p></li><li><p>Maksimovic, V, et al., &amp; Golocorbin-Kon, S (2020). Molecular mechanism of action and pharmacokinetic properties of methotrexate. <i>Molecular biology reports</i> 47(6) 4699–4708. DOI:<a href=&quot;https://doi.org/10.1007/s11033-020-05481-9&quot;>10.1007/s11033-020-05481-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32415503/&quot;>https://pubmed.ncbi.nlm.nih.gov/32415503</a></p></li><li><p>Vermeer, E, et al., &amp; de Jonge, R (2023). Oral Versus Subcutaneous Methotrexate in Immune-Mediated Inflammatory Disorders: an Update of the Current Literature. <i>Current rheumatology reports</i> 25(12) 276–284. DOI:<a href=&quot;https://doi.org/10.1007/s11926-023-01116-7&quot;>10.1007/s11926-023-01116-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37768405/&quot;>https://pubmed.ncbi.nlm.nih.gov/37768405</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AX03_1;
